Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

2.41USD
8 Dec 2017
Change (% chg)

$-0.12 (-4.74%)
Prev Close
$2.53
Open
$2.56
Day's High
$2.61
Day's Low
$2.41
Volume
10,550
Avg. Vol
22,125
52-wk High
$16.65
52-wk Low
$1.41

Summary

Name Age Since Current Position

M. James Barrett

74 2016 Independent Chairman of the Board

Meenu Chhabra

44 2014 President, Chief Executive Officer, Director

Helen Boudreau

51 2017 Chief Financial Officer, Principal Financial Officer, Treasurer

Po-Shun Lee

47 Executive Vice President, Chief Medical Officer

Brett Hagen

44 2017 Chief Accounting Officer, Vice President - Finance, Controller, Treasurer

Benito Munoz

55 2017 Chief Scientific Officer

Janet Smart

2014 Vice President - Intellectual Property & Legal Affaris

Geoffrey Gilmartin

49 2016 Chief Development Officer

Franklin Berger

67 2016 Independent Director

Jeffery Kelly

56 2006 Independent Director

Eric Rabinowitz

41 2016 Independent Director

Biographies

Name Description

M. James Barrett

Mr. M. James Barrett, Ph.D., is Independent Chairman of the Board of the Company. Dr. Barrett has been a general partner of New Enterprise Associates, Inc., or NEA, a venture capital fund, since 2001. He also serves on the boards of Clovis Oncology, Inc. (NASDAQ: CLVS), Galera Therapeutics, GlycoMimetics, Inc. (NASDAQ: GLYC), PhaseBio Pharmaceuticals Inc., Psyadon Pharmaceuticals, Inc., Roka Bioscience, Inc. (NASDAQ: ROKA), Placon Therapeutics, Inc., Senseonics Holdings, Inc. (NASDAQ: SENS) and Tarveda Therapeutics, Inc. He formerly served on the boards of, among others, CoGenesys Inc. (acquired by Teva Pharmaceutical Industries (NASDAQ: TEVA)), Iomai Corporation (acquired by Intercell AG (OTCBB: INRLF, INRLY)), MedImmune, Inc. (acquired by AstraZeneca plc (NYSE: AZN)), Pharmion Corp. (acquired by Celgene Corp. (NASDAQ: CELG)), Inhibitex, Inc. (NASDAQ: INHX, acquired by Bristol-Myers Squibb Company (NYSE: BMY)), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), LOXO Oncology, Inc. (NASDAQ: LOXO), Zosano Pharma Corporation (NASDAQ: ZSAN), Cerecor, Inc. (NASDAQ: CERC) and Peptimmune, Inc. Prior to NEA, Dr. Barrett served as Founder, Chairman and Chief Executive Officer of Sensors for Medicine and Science, Inc. (n/k/a Senseonics) and also led three NEA-funded companies, serving as Chairman and Chief Executive Officer of Genetic Therapy, Inc., President and Chief Executive Officer of Life Technologies, Inc. (acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO)), which was formed through the merger of GIBCO Corporation and Bethesda Research Labs, Inc., where Dr. Barrett was President and Chief Executive Officer. Previously, he worked in various divisions of SmithKline and French (now GlaxoSmithKline Plc (NYSE: GSK)). Dr. Barrett received his Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.

Meenu Chhabra

Ms. Meenu Chhabra is President, Chief Executive Officer, Director of the Company. Prior to joining Proteostasis, Ms. Chhabra served as the President and Chief Executive Officer since August 2007 at Allozyne, Inc., a private, Seattle, WA-based biotechnology company developing protein therapeutics based on a site selective bioconjugation platform spun out from Caltech and The Scripps Research Institute. While at Allozyne, she implemented a strategy to maximize the value of the proprietary platform by building a portfolio of risk reward balanced product candidates including antibody drug conjugates. This approach resulted in the lead program advancing directly from Phase 1 to Phase 3 and also triggered a strategic collaboration with a top tier pharmaceutical company that culminated in an eventual acquisition. Before joining Allozyne, Ms. Chhabra served as a Vice President of Business Development and licensing for Novartis AG, and as the chief business officer at BioXell S.p.A., a publically traded spin-off of Roche focused on urology and inflammation. She has also held a number of additional business development and sales roles in the pharmaceutical industry. She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto.

Helen Boudreau

Ms. Helen M. Boudreau serves as Chief Financial Officer, Principal Financial Officer, Treasurer of the Company. Ms. Boudreau has served as the Chief Financial Officer of FORMA Therapeutics, Inc. since October 2014. From September 2008 to September 2014, Ms. Boudreau worked at Novartis, including serving as the Chief Financial Officer of Novartis Corporation, the U.S. corporate arm of Novartis AG (NYSE: NVS), from November 2012 to September 2014, Vice President of Investor Relations from January 2012 to December 2012, and Vice President and Chief Financial Officer for Novartis Oncology, a global business unit, from September 2008 to January 2012. Before joining Novartis, Ms. Boudreau worked at Pfizer, Inc. (NYSE: PFE), where she served in multiple leadership positions, including Vice President of Finance, Customer Business Unit and Commercial Operations, Vice President of Finance, Research and Development, and the Senior Director of Financial Planning and Analysis. Prior to Pfizer, Ms. Boudreau held strategic and operational roles at Yum Brands/PepsiCo., McKinsey & Company, and Bank of America. Ms. Boudreau received a B.A. in Economics from the University of Maryland and an M.B.A. from the Darden School at the University of Virginia.

Po-Shun Lee

Mr. Po-Shun Lee, M.D. is Executive Vice President, Chief Medical Officer of the Company. Po-Shun is a pulmonary and critical care physician with industry and academia experiences. Prior to joining Proteostasis, he was at Novartis Institute for Biomedical Research leading cystic fibrosis and asthma programs from early development to proof of concept, and was Associate Medical Director at Vertex where he supported Kalydeco registration and led a CFTR corrector program to positive proof of concept. Before joining industry, Po-Shun was a physician-scientist at the Brigham and Women’s Hospital/Harvard Medical School where he was the scientific founder for 2 biotech companies, served as a principal investigator at the Pulmonary Division and the Translational Medicine Unit, Medical Director for the Pulmonary Function Lab, an attending physician in the Medical Intensive Care Unit, and an Instructor of Medicine at Harvard Medical School. His research interests during his academic career included endogenous inflammation control, aberrant cellular proliferation in rare lung diseases and gene therapy for cystic fibrosis. Po-Shun completed fellowship training at the Harvard Combined Pulmonary and Critical Care Program, received his MD degree from University of Pennsylvania School of Medicine and his BA degree from Johns Hopkins University.

Brett Hagen

Mr. Brett R. Hagen serves as Chief Accounting Officer, Vice President - Finance, Controller, Treasurer of the company. Mr. Hagen has been serving as the Company’s Controller since May 2016, Principal Accounting Officer since August 2016, Assistant Treasurer since October 2016, Vice President of Finance since February 2017, and Principal Financial Officer since March 2017. Previously, Mr. Hagen served as the controller for BIND Therapeutics, Inc. (NASDAQ: BIND), Vice President, Finance/Segment Controller of Boston Private Financial Holdings (NASDAQ: BPFH), Manager of SEC Financial Reporting and Technical Account of The Princeton Review, Controller of BioProcessors Corporation and held a number of positions at PricewaterhouseCoopers LLP. He received a B.A. from the University of Minnesota, a Master in Accountancy from Wright State University and a M.S. in Finance from Suffolk University.

Benito Munoz

Mr. Benito Munoz is Chief Scientific Officer of the Company. Mr. Ben joined Proteostasis in 2013, bringing more than 15 years’ experience in the biotech and Pharmaceutical industry in the areas of medicinal chemistry and drug discovery. In his former role at the Broad Institute, Dr. Munoz was responsible for directing and coordinating the oncology and infectious disease platform, and Molecular Library Probe Production Center Network (MLPCN) effort. He worked to design and implement a phenotypic screening platform which led to potent molecules with therapeutic potential in oncology, neuroscience, infectious and neglected diseases. He also worked at Merck Research Laboratories in Boston and San Diego.

Janet Smart

Ms. Janet Smart is the Vice President - Intellectual Property & Legal Affaris of the Company. She joined Proteostasis Therapeutics in 2011, bringing more than 20 years of experience in the biotech and pharmaceutical industry in the areas of drug development and intellectual property management. She has held senior positions at several companies and worked as a consultant with many early-stage biotechnology companies developing and implementing patent portfolio and licensing strategies, and conducting due diligence for various acquisitions and financings. Prior to joining Proteostasis Therapeutics, Dr. Smart was Senior Director of Legal Affairs at Anchor Therapeutics, Inc. where she was responsible for intellectual property and corporate matters. She received a J.D. from Franklin Pierce Law Center (now University of New Hampshire School of Law) and B.S., Master of Science and Ph.D. degrees from Northeastern University. Dr. Smart is a Patent Attorney registered to practice before the United States Patent and Trademark Office.

Geoffrey Gilmartin

Mr. Geoffrey S. Gilmartin, M.D., is Chief Development Officer of the Company. From January 2014 to August 2016, he held positions of increasing responsibility at AstraZeneca plc (NYSE:AZN), and most recently served as senior medical lead in global medicines developmentfor the benralizumab Phase 3 program in severe asthma. From January 2011 to January 2014, he held positions of increasing responsibility at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) including serving as medical lead for the Kalydeco® (ivacaftor) clinical development program, spearheading the initiation of Phase 3 trials to support label expansion studies for the drug. In addition to his leadership positions in the life sciences industry, Dr. Gilmartin is an attending physician in the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as director of the BIDMC Sleep Disorders Center and on its pulmonary leadership team. Dr. Gilmartin received a B.A. in History from Dartmouth College, a M.D. from Brown University School of Medicine and a Master of Medical Science in clinical research from Harvard Medical School.

Franklin Berger

Mr. Franklin M. Berger is Independent Director of the Company. Mr. Berger worked at Sectoral Asset Management as a co-founder of the small-cap focused NEMO Fund from January 2007 through May 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of BELLUS Health, Inc. (OTCPK: BLUSF), ESSA Pharma, Inc. (NASDAQ: EPIX), Immune Design Corp. (NASDAQ: IMDZ) and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), each of which is a public biotechnology company. Mr. Berger formerly served on the boards of Seattle Genetics, Inc. (NASDAQ: SGEN), Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) and Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which were public biopharmaceutical companies during Mr. Berger’s service as a director. Mr. Berger received a B.A. in International Relations and an M.A. in International Economics both from Johns Hopkins University and an M.B.A. from the Harvard Business School. He is also a Chartered Financial Analyst.

Jeffery Kelly

Mr. Jeffery W. Kelly, Ph.D., is Independent Director of the Company. he has served as the Chairman of Molecular and Experimental Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. From August 2000 to December 2008, he served as Dean of Graduate Studies at The Scripps Research Institute, and from July 2000 to December 2006, he also served as Vice President of Academic Affairs. Dr. Kelly also co-founded FoldRx Pharmaceuticals, Inc. and Misfolding Diagnostics Inc. He received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. We believe that Dr. Kelly’s long history with our company and scientific and technical expertise make him qualified to serve as a member of our Board of Directors.

Eric Rabinowitz

Mr. Eric B. Rabinowitz is Independent Director of the Company. He has served as Vice President of Corporate Development at Perrigo Company, plc since August 2014. Prior to Perrigo, from June 2010 to August 2014, Mr. Rabinowitz held several positions of increasing responsibility at Barclays Capital, Inc. including Vice President, Director, and Managing Director of Investment Banking, Health Care Mergers & Acquisitions. From February 2009 to May 2010 he served as Director and Executive Director, Investment Banking, Health Care group at Oppenheimer & Co. Inc. Mr. Rabinowitz also served as Associate and Vice President, Investment Banking, Health Care Group at Bear, Stearns & Co. Inc., continuing in the latter role at J.P. Morgan upon J.P. Morgan’s acquisition of Bear, Stearns & Co. Inc., Director of Finance at TheStreet.com, Financial Controller of North America BOO.com and Senior Accountant, Investment Companies Group at Deloitte and Touche, LLP. Mr. Rabinowitz earned a B.A. in Accounting from the University of Florida, Fischer School of Accounting and an M.B.A, with a concentration in Finance and Entrepreneurship, from The University of Chicago Booth School of Business.